Mechanistically, INHBA stabilizes the mitochondrial protein SLC25A10, activating the succinate/SUCNR1 and mtGSH/GPX4 axes, thus defining a therapeutically targetable driver of CRC progression. The gene discussed is GPX4; the disease is colorectal carcinoma.